CN104136026B - 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 - Google Patents

包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 Download PDF

Info

Publication number
CN104136026B
CN104136026B CN201280064763.1A CN201280064763A CN104136026B CN 104136026 B CN104136026 B CN 104136026B CN 201280064763 A CN201280064763 A CN 201280064763A CN 104136026 B CN104136026 B CN 104136026B
Authority
CN
China
Prior art keywords
compound
mao
glioma
cells
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280064763.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104136026A (zh
Inventor
大卫·S·巴斯肯
马丁·阿伦·夏普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methodist Hospital
Original Assignee
Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methodist Hospital filed Critical Methodist Hospital
Publication of CN104136026A publication Critical patent/CN104136026A/zh
Application granted granted Critical
Publication of CN104136026B publication Critical patent/CN104136026B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
CN201280064763.1A 2011-10-31 2012-10-31 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 Expired - Fee Related CN104136026B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553854P 2011-10-31 2011-10-31
US61/553,854 2011-10-31
PCT/US2012/062850 WO2013151584A1 (en) 2011-10-31 2012-10-31 Compound comprising a mao targeting/ seeker moiety for treating human gliomas

Publications (2)

Publication Number Publication Date
CN104136026A CN104136026A (zh) 2014-11-05
CN104136026B true CN104136026B (zh) 2018-03-02

Family

ID=47146760

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280064763.1A Expired - Fee Related CN104136026B (zh) 2011-10-31 2012-10-31 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物

Country Status (9)

Country Link
US (1) US10555936B2 (https=)
EP (2) EP2804604A1 (https=)
JP (1) JP6118808B2 (https=)
KR (1) KR102110794B1 (https=)
CN (1) CN104136026B (https=)
AU (1) AU2012376221A1 (https=)
CA (1) CA2887928A1 (https=)
HK (1) HK1204547A1 (https=)
WO (1) WO2013151584A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136026B (zh) 2011-10-31 2018-03-02 卫理公会医院研究所 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物
CN104710433B (zh) * 2014-01-23 2016-08-17 南京友怡医药科技有限公司 苯丁酸氮芥衍生物、制备方法及应用
WO2015153516A1 (en) * 2014-04-04 2015-10-08 University Of Florida Research Foundation Hdac inhibitor compounds and methods of treatment
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029333A1 (en) * 1993-06-07 1994-12-22 The Wellcome Foundation Limited Immunoreactive reagents employing monoamine oxidase
WO1998022110A1 (en) * 1996-11-20 1998-05-28 Virginia Tech Intellectual Properties, Inc. Prodrugs for the selective inhibition of monoamine oxidase-b

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5612329A (en) 1995-06-05 1997-03-18 University Of Maryland At Baltimore Diaziridinylpolyamine anti-cancer agents
KR20010102486A (ko) 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
WO2002038628A2 (en) 2000-11-07 2002-05-16 Symyx Technologies, Inc. Substituted pyridyl amine ligands, complexes and catalysts therefrom; processes for producing polyolefins therewith
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US7943586B2 (en) 2003-06-09 2011-05-17 The Trustees Of The University Of Pennsylvania Antineoplastic agents targeted via glut transporters
MXPA06013165A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
US7091205B2 (en) 2004-10-08 2006-08-15 Yu Show Fu Use of tetramethylpyrazine in the treatment of brain tumor
GB0513297D0 (en) 2005-06-29 2005-08-03 Glaxo Group Ltd Novel compounds
US20070275944A1 (en) 2006-04-05 2007-11-29 The Board Of Trustees Operating Michigan State University Antioxidants and methods of their use
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
PE20091561A1 (es) * 2008-02-29 2009-10-30 Array Biopharma Inc Compuestos inhibidores de raf y metodos para su uso
EP2141163A1 (de) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
EP3613729A1 (en) * 2009-06-10 2020-02-26 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds
EP2480531B1 (en) * 2009-09-21 2014-11-05 ChemoCentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
CN104136026B (zh) 2011-10-31 2018-03-02 卫理公会医院研究所 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029333A1 (en) * 1993-06-07 1994-12-22 The Wellcome Foundation Limited Immunoreactive reagents employing monoamine oxidase
WO1998022110A1 (en) * 1996-11-20 1998-05-28 Virginia Tech Intellectual Properties, Inc. Prodrugs for the selective inhibition of monoamine oxidase-b

Also Published As

Publication number Publication date
EP3815685A3 (en) 2021-10-13
KR20140128943A (ko) 2014-11-06
HK1204547A1 (en) 2015-11-27
CA2887928A1 (en) 2013-10-10
EP3815685A2 (en) 2021-05-05
WO2013151584A1 (en) 2013-10-10
EP2804604A1 (en) 2014-11-26
CN104136026A (zh) 2014-11-05
JP2014534227A (ja) 2014-12-18
KR102110794B1 (ko) 2020-05-15
AU2012376221A1 (en) 2014-06-19
US20140323513A1 (en) 2014-10-30
JP6118808B2 (ja) 2017-04-19
US10555936B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
JP6652923B2 (ja) クロロトキシンコンジュゲート及びその使用方法
US8597949B2 (en) Methods and compositions for modulating RAD51 and homologous recombination
US8853151B2 (en) Pro-drug complexes and related methods of use
US9238654B2 (en) Singleton inhibitors of sumoylation enzymes and methods for their use
AU2013362757B2 (en) Radiosensitizer compounds for use in combination with radiation
CN104136026B (zh) 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物
JP2019501225A (ja) Ｂ細胞リンパ腫２（ｂｃｌ−２）及び関連タンパク質の阻害
US12377087B2 (en) Compounds for the treatment of cancer
US20200140448A1 (en) Temozolomide compounds, polymers prepared therefrom, and method of treating a disease
TW202039439A (zh) ４（１ｈ）－奎諾酮衍生物及其用途
Hou et al. GSH-activatable camptothecin prodrug-loaded gold nanostars coated with hyaluronic acid for targeted breast cancer therapy via multiple radiosensitization strategies
US10266490B2 (en) Radioprotector compounds
US20110152252A1 (en) Shiga toxin b-subunit/chemotherapeutics conjugates
CN106232115A (zh) 用于治疗抗性的癌症的预防或治疗性组合物
JP2012012305A (ja) 抗がん剤の作用増強剤
ES2991018T3 (es) (N-(2-((2-bencilfenil)amino)-2-oxoetil)-L-naftamida) como agente terapéutico anticanceroso
US20140296265A1 (en) Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR
JP6382964B2 (ja) フタラジン誘導体
JP2019514969A (ja) 分子イメージング及びがんの免疫療法のためのδオピオイド受容体標的化薬
US11325905B2 (en) Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase
HK40041905A (en) Compound comprising a mao targeting/seeker moiety for treating human gliomas
KR20240088939A (ko) Dot1l 분해를 위한 소분자 및 이의 용도
WO2024148293A1 (en) Charged pi-conjugated molecules for the treatment of microbial infections
CN121240859A (zh) 用于治疗健康状况的组合物和制备和使用小分子的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Applicant address

Correct: Texas, USA

False: Texas, USA

Number: 45

Volume: 30

CI02 Correction of invention patent application

Correction item: Applicant address

Correct: Texas, USA

False: Texas, USA

Number: 45

Page: The title page

Volume: 30

ERR Gazette correction

Free format text: DELETE

RECT Rectification
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230310

Address after: Texas, USA

Patentee after: THE METHODIST Hospital

Address before: Texas, USA

Patentee before: THE METHODIST HOSPITAL Research Institute

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180302

CF01 Termination of patent right due to non-payment of annual fee